| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,743 | 0,773 | 04.11. | |
| 0,735 | 0,780 | 04.11. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.10. | CEL-SCI files to sell 1M shares of common stock for holders | ||
| 29.09. | CEL-SCI Aktie: Biotechfirma vor Quartalsbericht unter Druck | Die CEL-SCI Corporation, ein Biotechnologieunternehmen im klinischen Stadium, steht vor wichtigen Entwicklungen. Der Aktienkurs des Unternehmens, das sich auf Immuntherapien gegen Krebs und andere Krankheiten... ► Artikel lesen | |
| 16.09. | CEL-SCI Corporation: CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation | 5-year survival rate of 82.6% and 73% reduction in overall risk of death (hazard ratio of 0.27) are the strongest Multikine efficacy results reported to date, reflecting results in patients who... ► Artikel lesen | |
| 10.09. | CEL-SCI Corporation: CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress | Data to be presented on Saturday, September 14 and published via a press release before the open of market on Monday, September 16 CEL-SCI Corporation (NYSE American: CVM) today reported it... ► Artikel lesen | |
| 04.09. | CEL-SCI gains UK pediatric waiver for cancer treatment |
